A new abstract presented at the Society for Maternal-Fetal Medicine annual meeting shows a benefit for low-dose (81 mg) aspirin for women who have experienced a single pregnancy loss before 20 weeks (miscarriage) in the past year. The low-dose aspirin group of women had an absolute 9.2% increase in the rate of live birth. There was no increase in pregnancy loss, major fetal, neonatal, or maternal complications. The drug was well tolerated (small increase in minor vaginal bleeding and minor gastrointestinal upset) and the cost of treatment was low (approximately $2 for the pregnancy). The women took the medication prior to attempted pregnancy daily for up to 6 menstrual cycles, or if they conceived, up to the 36th week of pregnancy. They also took folic acid. For women who did not meet the criteria (single pregnancy loss prior to 20 weeks in the past year), there did not seem to be a benefit. The proposed mechanism is improved blood flow and placental attachment, and anti-inflammatory effects of aspirin. The final analysis is still pending on this study, and will be known as the EAGeR trial (The Effects of Aspirin in Gestation and Reproduction).
From: OB.Gyn. News, Susan London